S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
NASDAQ:CLDX

Celldex Therapeutics (CLDX) Stock Forecast, Price & News

$25.45
-0.79 (-3.01%)
(As of 05:24 PM ET)
Compare
Today's Range
$25.19
$26.34
50-Day Range
$26.24
$37.40
52-Week Range
$25.19
$48.40
Volume
435,198 shs
Average Volume
508,771 shs
Market Capitalization
$1.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$63.33

Celldex Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
148.9% Upside
$63.33 Price Target
Short Interest
Bearish
13.33% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.64) to ($3.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.32 out of 5 stars

Medical Sector

929th out of 968 stocks

Diagnostic Substances Industry

11th out of 12 stocks


CLDX stock logo

About Celldex Therapeutics (NASDAQ:CLDX) Stock

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. It has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

CLDX Price History

CLDX Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
H.C. Wainwright Reaffirms Their Buy Rating on Celldex (CLDX)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
SVB Securities Remains a Buy on Celldex (CLDX)
4 Analysts Have This to Say About Celldex Therapeutics
LifeSci Capital Reaffirms Their Buy Rating on Celldex (CLDX)
H.C. Wainwright Keeps Their Buy Rating on Celldex (CLDX)
See More Headlines
Receive CLDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CLDX Company Calendar

Last Earnings
8/08/2023
Today
9/22/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CLDX
CUSIP
15117B10
Employees
148
Year Founded
1983

Price Target and Rating

Average Stock Price Forecast
$63.33
High Stock Price Forecast
$73.00
Low Stock Price Forecast
$54.00
Forecasted Upside/Downside
+141.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-112,320,000.00
Net Margins
-3,475.70%
Pretax Margin
-3,475.70%

Debt

Sales & Book Value

Annual Sales
$2.36 million
Book Value
$6.93 per share

Miscellaneous

Free Float
45,512,000
Market Cap
$1.24 billion
Optionable
Optionable
Beta
2.14

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Anthony S. Marucci M.B.A.Mr. Anthony S. Marucci M.B.A. (Age 61)
    Founder, Pres, CEO & Director
    Comp: $1.14M
  • Dr. Tibor Keler (Age 64)
    Founder, Chief Scientific Officer & Exec. VP
    Comp: $739.03k
  • Mr. Sam Martin (Age 52)
    Sr. VP, CFO, Sec. & Treasurer
    Comp: $617.26k
  • Dr. Margo Heath-Chiozzi M.D. (Age 66)
    Sr. VP of Regulatory Affairs
    Comp: $614.12k
  • Dr. Diane C. Young M.D. (Age 66)
    Sr. VP & Chief Medical Officer
    Comp: $643.5k
  • Prof. Joseph P. Schlessinger Ph.D. (Age 78)
    Co-Founder & Member of Scientific Advisory Board
  • Ms. Sarah CavanaughMs. Sarah Cavanaugh (Age 48)
    Sr. VP of Corp. Affairs & Admin.
  • Patrick Till
    Sr. Director of Investor Relations & Corp. Communications
  • Mr. Freddy A. Jimenez Esq.Mr. Freddy A. Jimenez Esq. (Age 54)
    Sr. VP & Gen. Counsel
  • Dr. Ronald A. Pepin (Age 67)
    Chief Bus. Officer & Sr. VP













CLDX Stock - Frequently Asked Questions

Should I buy or sell Celldex Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CLDX shares.
View CLDX analyst ratings
or view top-rated stocks.

What is Celldex Therapeutics' stock price forecast for 2023?

4 Wall Street research analysts have issued 1 year price targets for Celldex Therapeutics' shares. Their CLDX share price forecasts range from $54.00 to $73.00. On average, they expect the company's stock price to reach $63.33 in the next twelve months. This suggests a possible upside of 141.4% from the stock's current price.
View analysts price targets for CLDX
or view top-rated stocks among Wall Street analysts.

How have CLDX shares performed in 2023?

Celldex Therapeutics' stock was trading at $44.57 at the beginning of 2023. Since then, CLDX shares have decreased by 41.1% and is now trading at $26.24.
View the best growth stocks for 2023 here
.

When is Celldex Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our CLDX earnings forecast
.

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.65). The biopharmaceutical company had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.67 million. Celldex Therapeutics had a negative net margin of 3,475.70% and a negative trailing twelve-month return on equity of 36.15%.

What ETFs hold Celldex Therapeutics' stock?

ETFs with the largest weight of Celldex Therapeutics (NASDAQ:CLDX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO).SPDR S&P Biotech ETF (XBI).

When did Celldex Therapeutics' stock split?

Celldex Therapeutics's stock reverse split on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Celldex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX).

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Who are Celldex Therapeutics' major shareholders?

Celldex Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.82%), State Street Corp (5.77%), Kynam Capital Management LP (5.50%), Polar Capital Holdings Plc (5.11%), Jennison Associates LLC (2.81%) and Point72 Asset Management L.P. (2.51%). Insiders that own company stock include Diane C Young, Elizabeth Crowley, Freddy A Jimenez, Richard M Wright, Samuel Bates Martin and Sarah Cavanaugh.
View institutional ownership trends
.

How do I buy shares of Celldex Therapeutics?

Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celldex Therapeutics' stock price today?

One share of CLDX stock can currently be purchased for approximately $26.24.

How much money does Celldex Therapeutics make?

Celldex Therapeutics (NASDAQ:CLDX) has a market capitalization of $1.24 billion and generates $2.36 million in revenue each year. The biopharmaceutical company earns $-112,320,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis.

How many employees does Celldex Therapeutics have?

The company employs 148 workers across the globe.

How can I contact Celldex Therapeutics?

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The official website for the company is www.celldex.com. The biopharmaceutical company can be reached via phone at (908) 454-7120, via email at ir@celldextherapeutics.com, or via fax at 908-454-1911.

This page (NASDAQ:CLDX) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -